Creavo appoints Andrew Mullen to Board of Directors

August 2019: UK medical device company Creavo Medical Technologies has appointed its Operations Director Andrew Mullen to its Board of Directors, a role which will see him lead on research and development (R&D) and regulatory affairs.
Andrew has held the Operations Director role at Creavo for over a year, where he advised the Board on regulatory matters and product development. He has been formally appointed to the Board in preparation for the company’s next regulatory phase, and ahead of commercialisation of its portable magnetocardiography (MCG) device Corsens® in the EMEA region.
Steve Parker, CEO of Creavo, said: “Andrew’s experience and leadership will be vital in esuring that we rigorously follow our roadmap for the development of Corsens®, which involves moving from product development to full-scale manufacturing ahead of commercialisation. R&D will be focused on ensuring the device is as user-friendly as possible within its intended emergency department setting, where we see it playing a transformative role in the rule out of acute coronary syndromes.”
Commenting on his appointment, Andrew said: “I am proud to join Creavo’s Board of Directors and I am committed to driving forward the next phase of development. We will be beginning several clinical studies early next year, which will provide us with crucial data to inform ongoing device improvement.”
Prior to joining Creavo in 2018, Andrew brought over 18 years’ experience in senior operational roles. Most recently, he held the role of Group Operations Director for global radiotherapy business Xstrahl where he was responsible for manufacturing, customer service, and quality & regulatory activities covering the UK, Germany and North American business units.
Corsens® has the potential to help physicians accurately and quickly rule out acute coronary syndromes with a simple, non-invasive scan within minutes at a patient’s bedside. Early identification of patients who are not at risk potentially reduces patient anxiety and saves the healthcare system valuable time, resources and bed space
 ENDS
 For further press information, please contact:
Georgie Phipps: +44 (0) 7515 589224 / Georgie.phipps@speedcomms.com
Max Hammond: +44 (0) 7866 748982 / Max.hammond@speedcomms.com
 Notes to editors
About Creavo Medical Technologies Ltd
Creavo Medical Technologies Ltd is a UK-based, privately held medical device company that is developing innovative diagnostic technologies. The company was formed in 2014 to bring to market ground-breaking technology developed by Professor Ben Varcoe, Chair of Quantum Information Science at Leeds University. It has facilities in Leeds and Coventry, UK.
Focused on improving front line patient care in acute medical settings, Creavo’s first application of this technology has the potential to meet an urgent clinical need in global cardiology to help physicians more accurately ‘rule out’ heart-related problems at the point of admission to emergency departments. Its medical device, Corsens®, is a battery-powered, portable unit that uses advanced quantum principles to capture, display and process electromagnetic fluctuations caused by heart activity.
Identifying non-risk patients early reduces patient anxiety and can save the hospitals valuable time, resources and bed space. Financially, the device has the potential to save individual hospitals hundreds of thousands of pounds per year.
For more information about Creavo, please visit: www.creavomedtech.com
The post Creavo appoints Andrew Mullen to Board of Directors appeared first on Creavo Medical Technologies.